FDA Approves TERIPARATIDE — Prasco Laboratories

Prasco Laboratories' earlier approval of the synthetic peptide teriparatide establishes a foundational market presence for the osteoporosis treatment, a branded product segment now experiencing intense competition. With widespread formulary access now firmly established by this 2002 authorization, the new entrant faces the critical challenge of differentiating its product offering against more recent, habit-forming alternatives.